Europe: lack of desire for new non-metastatic CRPC treatments from a payer perspective, but physicians are interested in any improvements.
By Brandon Goode, Analyst
15 July 2016
European payers indicated that there is not a major appetite for new drugs in the high-risk non-metastatic CRPC setting, as currently used ADT treatment is very inexpensive and high-risk markers are not universally viewed as an accurate indication of patient need. Moreover, non-metastatic disease is more commonly managed by surgeons, who have less experience with treatments more complex than standard ADT and castration. Nevertheless, both payers and key opinion leaders indicated that a new drug exhibiting a significant improvement in survival over standard treatments would be interesting, at the least.
“I think for clinicians, for the specialists, that [non-mCRPC] is still the ultimate patient they wish to help, but it’s by how much and when…they would hope…that the prevention reduces or delays and ultimately almost changes, lead to cure, so you have far fewer patients…And from a payer [perspective], when you’re looking at things on an individual basis, because by this point you usually are being asked for individual funding, it’s actually really hard to differentiate what the benefits will be, and what you can do really.”
National Health Service (NHS) England member
“[There is] very little [appetite for new drugs in non-metastatic CRPC] because it’s seen as a potential for an escalation of the costs. And the question is what use does it have for the patient?”
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>